immun-ops2020

Cambridge, MA and London, 18 June 2018 – The Dementia Discovery Fund (“DDF”) and Immuneering Corporation (“Immuneering”) today announce they have entered into a joint research collaboration to identify novel drug targets…

June 11th, 2018 — Immuneering’s CEO (Ben Zeskind) is scheduled to present an invited talk entitled “Data-driven identification and optimization of new medicines for cancer cachexia” at the 4th Cancer…

For more than 20 years, Copaxone (glatiramer acetate, Teva), a non-biological complex drug, has been a safe and effective treatment option for multiple sclerosis. In 2016, a follow-on glatiramer acetate…

Huntington Disease (HD) is an incurable autosomal dominant neurodegenerative disorder driven by an expansion repeat giving rise to the mutant huntingtin protein (mHtt), which is known to disrupt a multitude…

When a small molecule binds to the androgen receptor (AR), a conformational change can occur which impacts subsequent binding of co-regulator proteins and DNA. In order to accurately study this…

Five-year survival rates for patients whose cancer has metastasized are dramatically lower than for those with localized disease. However, few therapeutic development efforts specifically focus on inhibiting the process of…

Cachexia is a common cause of morbidity across multiple cancer types, yet remains largely under-studied especially in the realm of transcriptomics. An essential component of cancer cachexia is the induced…

Objective: Investigate the role of S1R in the mechanism of action of pridopidine.   Background: Sigma-1 receptor (S1R) is an ER chaperone protein involved in neuromodulation and neuroplasticity. Pridopidine is…